#NASDAQ #US #stock options #IDEAYA Biosciences #South San Francisco

IDEAYA Biosciences Grants Stock Options Incentives Under New Employment Plan

IDEAYA Biosciences, Inc., known for its commitment to precision medicine in oncology, has made significant moves in establishing new talent within its ranks. On February 26, 2026, the company announced through its Compensation Committee that it granted a total of 346,200 non-qualified stock options to three new employees. These grants are part of the 2023 Employment Inducement Incentive Award Plan, which aligns with Nasdaq Listing Rule 5635(c)(4).

About the Employment Inducement Plan

The 2023 Inducement Plan is specifically designed to serve as a strategic tool for attracting individuals who are not current employees of IDEAYA. This approach is particularly beneficial for incentivizing talent that may have been out of the workforce for a time or to attract experienced individuals from competing firms. The criteria laid out in Nasdaq's rule underscores a commitment to fair compensation practices while boosting employee morale and retention.

The granted stock options are priced at $31.90 per share, reflecting the closing share price from the Nasdaq Global Select Market on the date of the grant. This pricing ensures that the options are both attractive to new hires and reflective of current market conditions, enhancing the overall appeal of the offer.

Details of the Stock Options

Each of the new stock options comes with a 10-year term. Vested rights to these options will unfold over a four-year period, with 25% vesting on the first anniversary of the vesting commencement date. The remaining 75% will vest in equal monthly increments over the subsequent three years. However, it is essential to note that vesting is contingent upon the employee’s ongoing service to IDEAYA, ensuring consistent performance and commitment to the company’s goals.

This grant not only reflects IDEAYA's dedication to building a strong team but also highlights its strategy to create a workforce aligned with the company's mission of advancing precision oncology therapies. With a deep pipeline aimed at tackling complex cancer treatments, IDEAYA remains focused on its goal of delivering targeted and effective therapies that address genetic drivers of diseases.

IDEAYA’s Commitment to Precision Medicine

IDEAYA Biosciences focuses on the discovery and development of innovative cancer therapies, utilizing a multifaceted approach that combines expertise in small-molecule drug discovery with advanced capabilities in structural biology and bioinformatics. The company is dedicated to identifying and validating translational biomarkers, which are crucial for developing customized therapies aimed at specific molecular targets. This focus is well illustrated through their product candidates that target synthetic lethality and employ antibody-drug conjugates or ADCs, aiming to enhance effectiveness against solid tumor indications.

The mission at IDEAYA is to bring forth a new era of cancer treatment strategies that are personalized, effective, and selective, aiming to fundamentally improve patient outcomes and alter disease trajectories for individuals afflicted by cancer. As IDEAYA continues to expand its team with talented individuals through strategies like the 2023 Inducement Plan, it is steadfast in its commitment to innovation in cancer care and precision medicine advancements.

For more information about IDEAYA Biosciences or to inquire about career opportunities, please refer to their official investor and media contact, Joshua Bleharski, Ph.D., Chief Financial Officer at IDEAYA Biosciences.

• ---

This strategic move by IDEAYA illuminates the competitive landscape surrounding talent acquisition in the biotechnology sector, where attracting skilled employees is directly linked to fostering innovation and ultimately addressing significant health challenges like cancer.